Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma

Journal of Pathology

Volumn 217, Issue 1, 2009, Pages 21-31

  Ohtani, H ^a   Jin, Z ^b   Takegawa, S ^b   Nakayama, T ^b   Yoshie, O ^b  

^a NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CXCL10 (IP 10); CXCL9 (MIG); CXCR3; Epstein barr virus; Gastric carcinoma; Lymphoid stroma

Indexed keywords

CD209 ANTIGEN; CD83 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; FASCIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; KI 67 ANTIGEN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINE CXCL9; DENDRITIC CELLS; EPSTEIN-BARR VIRUS INFECTIONS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM STAGING; RECEPTORS, CXCR3; RNA, MESSENGER; STOMACH NEOPLASMS; STROMAL CELLS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 58649094649     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2448     Document Type: Article

References (35)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991- 998.
2. + T-cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-3494.
3. +/ regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795) :1960-1964.
5. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006;86:231-245.
6. Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, et al. Invasive breast carcinoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, Tavassoli FA, Deville P (eds). IARC Press: Lyon 2003; 28-29.
7. Chan JKC, Pilch BZ, Bray F, Wening, et al. Nasopharyngeal carcinoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (eds). IARC Press: Lyon, 2005; 85-97.
8. Watanabe H, Enjoji M, Imai T. Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer 1976;38:232-243.
9. Minamoto T, Mai M, Watanabe K, Ooi A, Kitamura T, Takahashi Y, et al. Medullary carcinoma with lymphocytic infiltration of the stomach. Clinicopathologic study of 27 cases and immuno-histochemical analysis of the subpopulations of infiltrating lymphocytes in the tumor. Cancer 1990;66:945-952.
10. Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. Epstein-Barr virus in gastric carcinoma. Am J Pathol 1993;143:1250-1254.
11. + T lymphocytes. Lab Invest 1996;75:67-76.
12. + cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. J Clin Invest 1999;104:163-171.
13. van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, et al. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol 2006;30:59-65.
14. Koriyama C, Akiba S, Itoh T, Kijima Y, Sueyoshi K, Corvalan A, et al. Prognostic significance of Epstein-Barr virus involvement in gastric carcinoma in Japan. Int J Mol Med 2002;10:635-639.
15. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001;78:57-110.
16. + T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 2003;163:261-268.
17. + cytoplasmic granules in actively inflammatory lesions of human chronic gastritis. Lab Invest 2004;84:368-375.
18. + granulomas in Crohn's disease: a pivotal site of Th1-shifted immune response? Lab Invest 2005;85:137-145.
19. + Tlym-phocytes in human colorectal carcinoma. Int J Cancer. 2005;116:949-956.
20. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, et al. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 2007;38:1676-1687.
21. Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol 2007;8:1255-1265.
22. Okamura T, Kodama Y, Kamegawa T, Sano C, Kumashiro R, Inokuchi K. Gastric carcinoma with lymphoid stroma: correlation to reactive hyperplasia in regional lymph nodes and prognosis. Jpn J Surg 1983;13:177-183.
23. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
24. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-1174.
25. + regulatory T cells. J Exp Med 2001;194:847-853.
26. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-α2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8 effector T cells. J Leuk Biol 2002;71:669-676.
27. Lebre MC, Burwell T, Vieira PL, Lora J, Coyle AJ, Kapsenberg ML, et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol 2005;83:525-535.
28. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006;97:780-786.
29. Tominaga M, Iwashita Y, Ohta M, Shibata K, Ishio T, Ohmori N, et al. Antitumor effects of the MIG and IP-10 genes transferred with poly(D,L-2,4-diaminobutyric acid) on murine neuroblastoma. Cancer Gene Ther 2007;14:696-705.
30. Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, et al. CXC chemokine ligand 9/monokine induced by IFN-γ production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol 2007;178:2278-2286.
31. Hirano S, Iwashita Y, Sasaki A, Kai S, Ohta M, Kitano S. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes. J Gastroenterol Hepatol 2007;22:690-696.
32. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006;6:205-217.
33. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907.
34. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477.
35. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008;9:970- 980.